BACKGROUND: Myeloproliferative neoplasm (MPN) has been associated with pulmonary hypertension (PH) on the basis of small observational studies, but the mechanism and clinical significance of PH in MPN are not well established. The aims of this study were to expand understanding of PH in a well-characterized MPN cohort via study of PH-related symptoms, mortality risk, and cardiac remodeling sequalae of PH using quantitative echocardiographic methods. METHODS: The population comprised a retrospective cohort of patients with MPN who underwent transthoracic echocardiography: Doppler-derived pulmonary arterial systolic pressure applied established cutoffs for PH (≥35 mm Hg) and advanced PH (≥50 mm Hg); right ventricular (RV) performance was assessed via conventional indices (tricuspid annular plane systolic excursion [TAPSE], S') and global longitudinal strain. Symptoms and mortality were discerned via standardized review. RESULTS: Three hundred one patients were studied; 56% had echocardiography-demonstrated PH (20% advanced) paralleling a high prevalence (67%) among patients with invasively quantified PASP. PH was associated with adverse left ventricular (LV) remodeling indices, including increased myocardial mass and diastolic dysfunction (P ≤ .001 for all): LV mass and filling pressure (P < .01) were associated with PH independent of LV ejection fraction. RV dysfunction by strain and TAPSE and S' increased in relation to PH (P ≤ .001) and was about threefold greater among patients with advanced PH compared with those without PH. Patients with RV dysfunction were more likely to report dyspnea, as were those with advanced PH (P < .05). During median follow-up of 2.2 years, all-cause mortality was 27%. PH grade (hazard ratio, 1.9; 95% CI, 1.1-3.0; P = .012) and TAPSE- and S'-demonstrated RV dysfunction (hazard ratio, 3.3; 95% CI, 1.3-8.2; P = .01) were independently associated with mortality; substitution of global longitudinal strain for TAPSE and S' yielded similar associations of RV dysfunction with death (hazard ratio, 3.2; 95% CI, 1.5-6.7; P = .003) independent of PH. CONCLUSIONS: PH is highly prevalent in patients with MPN and is linked to LV diastolic dysfunction; echocardiography-quantified RV dysfunction augments risk for mortality independent of PH.
BACKGROUND: Myeloproliferative neoplasm (MPN) has been associated with pulmonary hypertension (PH) on the basis of small observational studies, but the mechanism and clinical significance of PH in MPN are not well established. The aims of this study were to expand understanding of PH in a well-characterized MPN cohort via study of PH-related symptoms, mortality risk, and cardiac remodeling sequalae of PH using quantitative echocardiographic methods. METHODS: The population comprised a retrospective cohort of patients with MPN who underwent transthoracic echocardiography: Doppler-derived pulmonary arterial systolic pressure applied established cutoffs for PH (≥35 mm Hg) and advanced PH (≥50 mm Hg); right ventricular (RV) performance was assessed via conventional indices (tricuspid annular plane systolic excursion [TAPSE], S') and global longitudinal strain. Symptoms and mortality were discerned via standardized review. RESULTS: Three hundred one patients were studied; 56% had echocardiography-demonstrated PH (20% advanced) paralleling a high prevalence (67%) among patients with invasively quantified PASP. PH was associated with adverse left ventricular (LV) remodeling indices, including increased myocardial mass and diastolic dysfunction (P ≤ .001 for all): LV mass and filling pressure (P < .01) were associated with PH independent of LV ejection fraction. RV dysfunction by strain and TAPSE and S' increased in relation to PH (P ≤ .001) and was about threefold greater among patients with advanced PH compared with those without PH. Patients with RV dysfunction were more likely to report dyspnea, as were those with advanced PH (P < .05). During median follow-up of 2.2 years, all-cause mortality was 27%. PH grade (hazard ratio, 1.9; 95% CI, 1.1-3.0; P = .012) and TAPSE- and S'-demonstrated RV dysfunction (hazard ratio, 3.3; 95% CI, 1.3-8.2; P = .01) were independently associated with mortality; substitution of global longitudinal strain for TAPSE and S' yielded similar associations of RV dysfunction with death (hazard ratio, 3.2; 95% CI, 1.5-6.7; P = .003) independent of PH. CONCLUSIONS:PH is highly prevalent in patients with MPN and is linked to LV diastolic dysfunction; echocardiography-quantified RV dysfunction augments risk for mortality independent of PH.
Authors: C Wickenhauser; J Thiele; J Lorenzen; B Schmitz; S Frimpong; K Schramm; I Neumann; R Zankovich; R Fischer Journal: Leukemia Date: 1999-03 Impact factor: 11.528
Authors: Jiwon Kim; Antonino Di Franco; Tania Seoane; Aparna Srinivasan; Polydoros N Kampaktsis; Alexi Geevarghese; Samantha R Goldburg; Saadat A Khan; Massimiliano Szulc; Mark B Ratcliffe; Robert A Levine; Ashley E Morgan; Pooja Maddula; Meenakshi Rozenstrauch; Tara Shah; Richard B Devereux; Jonathan W Weinsaft Journal: Circ Cardiovasc Imaging Date: 2016-11 Impact factor: 7.792
Authors: Marco van Kessel; David Seaton; Jonathan Chan; Akira Yamada; Fiona Kermeen; Christian Hamilton-Craig; Thomas Butler; Surendran Sabapathy; Norman Morris Journal: Int J Cardiovasc Imaging Date: 2016-03-01 Impact factor: 2.357
Authors: Richard B Devereux; Kristian Wachtell; Eva Gerdts; Kurt Boman; Markku S Nieminen; Vasilios Papademetriou; Jens Rokkedal; Katherine Harris; Peter Aurup; Björn Dahlöf Journal: JAMA Date: 2004-11-17 Impact factor: 56.272
Authors: Jonathan Kochav; Jennifer Chen; Lakshmi Nambiar; Hannah W Mitlak; Arielle Kushman; Razia Sultana; Evelyn Horn; Arindam RoyChoudhury; Richard B Devereux; Jonathan W Weinsaft; Jiwon Kim Journal: J Am Soc Echocardiogr Date: 2021-03-11 Impact factor: 7.722
Authors: Jiwon Kim; Alexander Volodarskiy; Razia Sultana; Meridith P Pollie; Brian Yum; Lakshmi Nambiar; Romina Tafreshi; Hannah W Mitlak; Arindam RoyChoudhury; Evelyn M Horn; Ingrid Hriljac; Nupoor Narula; Sijun Kim; Lishomwa Ndhlovu; Parag Goyal; Monika M Safford; Leslee Shaw; Richard B Devereux; Jonathan W Weinsaft Journal: J Am Coll Cardiol Date: 2020-10-27 Impact factor: 24.094